Evidence snapshot: The strongest human evidence comes from a 2-year randomized controlled trial in 65 healthy older adults (Nass et al., 2008, Annals of Internal Medicine) showing sustained GH/IGF-1 increases and preserved fat-free mass, plus an earlier short-term human polysomnography study on sleep (Copinschi et al., 1997, Neuroendocrinology, PMID 9349662)
In preclinical models, BPC 157 has been shown to modulate a broad range of cellular and molecular pathways
What exists is a growing body of preclinical data, early-phase human research, and a developing clinical consensus among peptide-prescribing physicians that points toward a relatively narrow therapeutic window
Skeletal muscle can release medium-chain acylcarnitines (MCACs) into the circulation to remove acyl-CoA, which can be detrimental to cellular function, particularly when the supply of energy substrates exceeds the oxidative capacity of the TCA cycle